| Literature DB >> 29941841 |
Adeena Tahir1, Rima D Alharthy2, Saadia Naseem3, Natasha Mahmood4, Mahmood Ahmed5, Khuram Shahzad6, Malik Nadeem Akhtar7, Abdul Hameed8, Irfan Sadiq9, Haq Nawaz10, Muhammad Muddassar11.
Abstract
The bromodomain containing protein 4 (BRD4) recognizes acetylated histone proteins and plays numerous roles in the progression of a wide range of cancers, due to which it is under intense investigation as a novel anti-cancer drug target. In the present study, we performed three-dimensional quantitative structure activity relationship (3D-QSAR) molecular modeling on a series of 60 inhibitors of BRD4 protein using ligand- and structure-based alignment and different partial charges assignment methods by employing comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) approaches. The developed models were validated using various statistical methods, including non-cross validated correlation coefficient (r²), leave-one-out (LOO) cross validated correlation coefficient (q²), bootstrapping, and Fisher's randomization test. The highly reliable and predictive CoMFA (q² = 0.569, r² = 0.979) and CoMSIA (q² = 0.500, r² = 0.982) models were obtained from a structure-based 3D-QSAR approach using Merck molecular force field (MMFF94). The best models demonstrate that electrostatic and steric fields play an important role in the biological activities of these compounds. Hence, based on the contour maps information, new compounds were designed, and their binding modes were elucidated in BRD4 protein's active site. Further, the activities and physicochemical properties of the designed molecules were also predicted using the best 3D-QSAR models. We believe that predicted models will help us to understand the structural requirements of BRD4 protein inhibitors that belong to quinolinone and quinazolinone classes for the designing of better active compounds.Entities:
Keywords: 3D-QSAR; BRD4 protein inhibitors; CoMFA; CoMSIA; molecular docking
Mesh:
Substances:
Year: 2018 PMID: 29941841 PMCID: PMC6099705 DOI: 10.3390/molecules23071527
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Alignment of dataset compounds (a) Ligand-based alignment of the conformers obtained from omega software; (b) Structure-based alignment of docked compounds.
Statistical Results of Structure- and Ligand-Based Models.
| MMFF94 Charges | Structure-Based Model | Ligand-Based Model | ||
|---|---|---|---|---|
| 50 Compounds | ||||
| Parameters | CoMFA | CoMSIA | CoMFA | CoMSIA |
|
| 5 | 6 | 2 | 6 |
|
| 0.569 | 0.500 | 0.399 | 0.403 |
|
| 0.979 | 0.982 | 0.873 | 0.873 |
|
| 0.102 | 0.094 | 0.251 | 0.251 |
|
| 336.723 | 396.442 | 49.120 | 49.133 |
|
| 0.816 | 0.834 | 0.762 | 0.769 |
|
| 0.470 | 0.130 | 0.474 | 0.120 |
|
| 0.530 | 0.345 | 0.526 | 0.328 |
|
| - | 0.254 | - | 0.213 |
|
| - | 0.127 | - | 0.166 |
|
| - | 0.144 | - | 0.173 |
|
| 0.988 | 0.988 | 0.915 | 0.927 |
|
| 0.004 | 0.005 | 0.066 | 0.058 |
Merck molecular force field (MMFF94); comparative molecular field analysis (CoMFA); comparative molecular similarity indices analysis (CoMSIA); ONC = optimal number of components; q2 = cross-validated correlation coefficient; r2 = determination coefficient; r2ncv = non-cross validated coefficient; SEE = standard error of estimate; F = Fischer’s F-value; Pred-r2 = predictive r2; r2bs = r2 obtained after bootstrapping; and SDbs = bootstrapping standard deviation.
Figure 2Experimental vs predicted biological activities (pIC50) values from best structure-based three-dimensional quantitative structure activity relationship (3D-QSAR) models.
Figure 3Contour maps of structure-based model on the most active compound (42) as template (sticks). (a) CoMFA steric field contour maps; (b) CoMFA electrostatic fields contour maps; (c) CoMSIA hydrophobic field contour maps; (d) CoMSIA hydrogen bond acceptor fields contour maps; and (e) CoMSIA hydrogen bond donor fields contour maps.
Figure 4Docking pose of the ligands in the active site of the BRD4 protein (cyan) along with water molecules (red and white sticks). (A) Superposition of best pose of the co-crystal ligand (green) on the bound ligand (magenta) after redocking experiments; (B) Superposition of the docked pose of the most active compound (yellow) on the co-crystal ligand (magenta). The yellow dotted lines represent hydrogen bonds.
Predicted physicochemical/pharmacokinetic properties of the newly designed compounds.
| Comp | MW | HBD | HBA | QPlogPo/w | QPlogHERG | QPCaco2 | QPlogBB | QPlogKhsa |
|---|---|---|---|---|---|---|---|---|
|
| 405.41 | 6 | 7 | 1.232 | −5.899 | 15.239 | −2.972 | −0.046 |
|
| 416.43 | 5 | 6 | 2.732 | −6.434 | 76.171 | −2.227 | 0.358 |
|
| 404.38 | 6 | 6 | 1.606 | −6.432 | 23.449 | −2.752 | −0.022 |
|
| 403.39 | 7 | 5 | 1.373 | −6.352 | 13.145 | −3.049 | −0.067 |
|
| 432.49 | 4 | 8 | 2.371 | −6.23 | 62.067 | −2.187 | 0.246 |
|
| 432.49 | 5 | 5 | 3.191 | −6.294 | 80.298 | −2.084 | 0.478 |
|
| 451.31 | 4 | 4 | 4.433 | −6.894 | 195.227 | −1.354 | 0.717 |
|
| 420.47 | 3 | 5 | 3.653 | −6.669 | 107.71 | −1.933 | 0.722 |
|
| 431.88 | 6 | 5 | 2.937 | −6.857 | 44.197 | −2.357 | 0.332 |
|
| 451.41 | 4 | 5 | 3.546 | −6.692 | 75.418 | −1.887 | 0.54 |
MW = molecular weight, HBD = hydrogen bond donor, HBA = hydrogen bond acceptor, QPlogPo/w = octanol/water partition coefficient (recommended rage −2.0 to 6.5), QPlogHERG = blockage of HERG K+ channels (recommended range <−5), QPCaco2 = Caco2 cell permeability (recommended range <25 poor, >500 great), QPlogBB = brain/blood partition coefficient (recommended range −3.0 to 1.2), and QPlogKhsa = binding to human serum albumin (recommended range −1.5 to 1.5).
Newly designed compounds structures with their docking scores and predicted biological activities.
| Substituents | Glide-Score | Predicted pIC50 | |||
|---|---|---|---|---|---|
| No. | R | R′ | CoMFA Model | CoMSIA Model | |
| 1 |
|
| −7.348 | 7.675 | 6.757 |
| 2 |
|
| −7.140 | 7.293 | 6.523 |
| 3 |
|
| −7.775 | 7.116 | 6.219 |
| 4 |
|
| −7.010 | 7.113 | 6.074 |
| 5 |
|
| −5.953 | 6.922 | 6.255 |
| 6 |
|
| −6.691 | 6.740 | 6.614 |
| 7 |
|
| −6.959 | 6.664 | 6.612 |
| 8 |
|
| −6.421 | 6.367 | 7.058 |
| 9 |
|
| −6.429 | 6.347 | 7.035 |
| 10 |
|
| −7.352 | 6.302 | 6.123 |
Figure 5Docking pose of the newly designed compounds in the active site of the BRD4 protein (cyan) along with water molecules (red and white sticks). The yellow dotted lines represent hydrogen bonds.
Structures of the BRD4 inhibitors and their biological activities.
| No. | R1 | X | pIC50 | No. | R1 | X | pIC50 |
|---|---|---|---|---|---|---|---|
| 1 |
| N | 5.3 | 8 |
| N | 6.4 |
| 2 |
| N | 5.7 | 9 |
| N | 6.3 |
| 3 |
| N | 5.3 | 10 |
| N | 6.1 |
| 4 |
| N | 6.7 | 11 |
| N | 6.0 |
| 5 |
| N | 6.6 | 12 |
| N | 6.0 |
| 6 |
| N | 6.6 | 13 |
| N | 5.6 |
| 7* |
| N | 6.4 | ||||
|
|
|
|
|
|
|
|
|
| 14 |
| 4.6 | 27 |
| N | 4.6 | |
| 15 |
| 4.4 | 28 * |
| N | 3.8 | |
| 16* |
| 5.3 | 29 |
| N | 4.8 | |
| 17 |
| 4.3 | 30 * |
| N | 4.9 | |
| 18 |
| CH | 5.0 | 31 |
| N | 4.9 |
| 19 |
| N | 4.7 | 32 |
| N | 5.2 |
| 20 |
| CH | 5.2 | 33 * |
| N | 5.5 |
| 21 |
| N | 5.4 | 34 |
| N | 5.3 |
| 22* |
| CH | 5.2 | 35 |
| N | 5.1 |
| 23 |
| N | 4.8 | 36 |
| N | 5.4 |
| 24 |
| N | 4.4 | 37 |
| N | 5.5 |
| 25 |
| N | 4.9 | 38 |
| N | 5.4 |
| 26 |
| N | 4.6 | ||||
|
|
|
|
|
|
|
|
|
| 39 |
| N | 6.1 | 50 * |
| N | 5.6 |
| 40 |
| N | 6.0 | 51 |
| N | 5.5 |
| 41 |
| N | 6.2 | 52 |
| N | 5.9 |
| 42 |
| N | 6.9 | 53 |
| N | 5.9 |
| 43 |
| N | 5.7 | 54 |
| N | 5.2 |
| 44 |
| N | 6.1 | 55 * |
| N | 5.4 |
| 45 |
| N | 5.5 | 56 |
| N | 5.1 |
| 46 * |
| N | 5.3 | 57 |
| N | 5.7 |
| 47 |
| N | 5.9 | 58 |
| N | 6.1 |
| 48 * |
| N | 5.2 | 59 |
| N | 5.9 |
| 49 |
| N | 6.0 | 60 |
| N | 4.8 |
* Test set compounds.